Understanding how to improve immunotherapy responses in liver cancer linked to fatty liver disease
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
This study is looking into why people with liver cancer caused by fatty liver disease don't respond as well to immunotherapy, and it aims to find better treatment options by combining different therapies and identifying markers that can help predict who will benefit the most.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10899678 on NIH RePORTER |
What this research studies
This research investigates why patients with hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) have lower responses to immunotherapy. The team will explore the role of specific immune cells and genetic factors that affect treatment outcomes. By combining immune checkpoint inhibitors with other targeted therapies, they aim to enhance the effectiveness of treatment for these patients. The study will also identify potential biomarkers that could predict which patients are likely to benefit from these therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma stemming from non-alcoholic steatohepatitis.
Not a fit: Patients with hepatocellular carcinoma not related to non-alcoholic steatohepatitis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with liver cancer associated with fatty liver disease.
How similar studies have performed: Previous research has shown promising results in enhancing immunotherapy responses through combination therapies, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Llovet, Josep M — Icahn School of Medicine at Mount Sinai
- Study coordinator: Llovet, Josep M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.